Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1962 1
1963 1
1964 1
1990 1
1995 1
2001 4
2003 1
2004 3
2006 3
2007 1
2008 4
2009 2
2010 3
2011 2
2012 5
2013 4
2016 2
2018 4
2019 3
2020 2
2021 2
2022 1
2023 3
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

51 results

Results by year

Filters applied: . Clear all
Page 1
Tolvaptan in patients with autosomal dominant polycystic kidney disease.
Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Grantham JJ, Higashihara E, Perrone RD, Krasa HB, Ouyang J, Czerwiec FS; TEMPO 3:4 Trial Investigators. Torres VE, et al. N Engl J Med. 2012 Dec 20;367(25):2407-18. doi: 10.1056/NEJMoa1205511. Epub 2012 Nov 3. N Engl J Med. 2012. PMID: 23121377 Free PMC article. Clinical Trial.
Renoprotective effects of combination treatment with sodium-glucose cotransporter inhibitors and GLP-1 receptor agonists in patients with type 2 diabetes mellitus according to preceding medication.
Kobayashi K, Toyoda M, Tone A, Kawanami D, Suzuki D, Tsuriya D, Machimura H, Shimura H, Takeda H, Yokomizo H, Takeshita K, Chin K, Kanasaki K, Miyauchi M, Saburi M, Morita M, Yomota M, Kimura M, Hatori N, Nakajima S, Ito S, Tsukamoto S, Murata T, Matsushita T, Furuki T, Hashimoto T, Umezono T, Muta Y, Takashi Y, Tamura K. Kobayashi K, et al. Among authors: umezono t. Diab Vasc Dis Res. 2023 Nov-Dec;20(6):14791641231222837. doi: 10.1177/14791641231222837. Diab Vasc Dis Res. 2023. PMID: 38096503 Free PMC article.
Comparison of renal outcomes between sodium glucose co-transporter 2 inhibitors and glucagon-like peptide 1 receptor agonists.
Kobayashi K, Toyoda M, Hatori N, Sakai H, Furuki T, Chin K, Kimura M, Saito N, Kanaoka T, Aoyama T, Umezono T, Ito S, Suzuki D, Takeda H, Minagawa F, Degawa H, Machimura H, Hishiki T, Umezawa S, Shimura H, Nakajima S, Yamamoto H, Sato K, Miyakawa M, Terauchi Y, Tamura K, Kanamori A. Kobayashi K, et al. Among authors: umezono t. Diabetes Res Clin Pract. 2022 Mar;185:109231. doi: 10.1016/j.diabres.2022.109231. Epub 2022 Feb 5. Diabetes Res Clin Pract. 2022. PMID: 35131376
A variant within the FTO confers susceptibility to diabetic nephropathy in Japanese patients with type 2 diabetes.
Taira M, Imamura M, Takahashi A, Kamatani Y, Yamauchi T, Araki SI, Tanaka N, van Zuydam NR, Ahlqvist E, Toyoda M, Umezono T, Kawai K, Imanishi M, Watada H, Suzuki D, Maegawa H, Babazono T, Kaku K, Kawamori R; SUMMIT Consortium; Groop LC, McCarthy MI, Kadowaki T, Maeda S. Taira M, et al. Among authors: umezono t. PLoS One. 2018 Dec 19;13(12):e0208654. doi: 10.1371/journal.pone.0208654. eCollection 2018. PLoS One. 2018. PMID: 30566433 Free PMC article.
Hypertrophy and loss of podocytes in diabetic nephropathy.
Miyauchi M, Toyoda M, Kobayashi K, Abe M, Kobayashi T, Kato M, Yamamoto N, Kimura M, Umezono T, Suzuki D. Miyauchi M, et al. Among authors: umezono t. Intern Med. 2009;48(18):1615-20. doi: 10.2169/internalmedicine.48.2137. Epub 2009 Sep 15. Intern Med. 2009. PMID: 19755763 Free article.
Blood pressure after treatment with sodium-glucose cotransporter 2 inhibitors influences renal composite outcome: Analysis using propensity score-matched models.
Kobayashi K, Toyoda M, Hatori N, Furuki T, Sakai H, Umezono T, Ito S, Suzuki D, Takeda H, Minagawa F, Degawa H, Yamamoto H, Machimura H, Chin K, Hishiki T, Takihata M, Aoyama K, Umezawa S, Minamisawa K, Aoyama T, Hamada Y, Suzuki Y, Hayashi M, Hatori Y, Sato K, Miyakawa M, Tamura K, Kanamori A. Kobayashi K, et al. Among authors: umezono t. J Diabetes Investig. 2021 Jan;12(1):74-81. doi: 10.1111/jdi.13318. Epub 2020 Jul 10. J Diabetes Investig. 2021. PMID: 32506833 Free PMC article.
The concomitant use of sodium-glucose co-transporter 2 inhibitors improved the renal outcome of Japanese patients with type 2 diabetes treated with glucagon-like peptide 1 receptor agonists.
Kobayashi K, Toyoda M, Hatori N, Tsukamoto S, Kimura M, Sakai H, Furuki T, Chin K, Kanaoka T, Aoyama T, Umezono T, Ito S, Suzuki D, Takeda H, Degawa H, Hishiki T, Shimura H, Nakajima S, Miyauchi M, Yamamoto H, Hatori Y, Hayashi M, Sato K, Miyakawa M, Terauchi Y, Tamura K, Kanamori A. Kobayashi K, et al. Among authors: umezono t. Cardiovasc Endocrinol Metab. 2023 Sep 28;12(4):e0292. doi: 10.1097/XCE.0000000000000292. eCollection 2023 Dec. Cardiovasc Endocrinol Metab. 2023. PMID: 37779602 Free PMC article.
Expression of alpha-actinin-4 in human diabetic nephropathy.
Kimura M, Toyoda M, Kato M, Kobayashi K, Abe M, Kobayashi T, Miyauchi M, Yamamoto N, Umezono T, Suzuki D. Kimura M, et al. Among authors: umezono t. Intern Med. 2008;47(12):1099-106. doi: 10.2169/internalmedicine.47.0352. Epub 2008 Jun 16. Intern Med. 2008. PMID: 18552466 Free article.
Retrospective Analysis of the Renoprotective Effects of Long-Term Use of Six Types of Sodium-Glucose Cotransporter 2 Inhibitors in Japanese Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease.
Kobayashi K, Toyoda M, Hatori N, Saito N, Kanaoka T, Sakai H, Furuki T, Umezono T, Ito S, Suzuki D, Takeda H, Minagawa F, Degawa H, Yamamoto H, Machimura H, Chin K, Hishiki T, Takihata M, Aoyama K, Umezawa S, Minamisawa K, Aoyama T, Hamada Y, Suzuki Y, Hayashi M, Hatori Y, Sato K, Miyakawa M, Tamura K, Kanamori A. Kobayashi K, et al. Among authors: umezono t. Diabetes Technol Ther. 2021 Feb;23(2):110-119. doi: 10.1089/dia.2020.0165. Epub 2020 Aug 13. Diabetes Technol Ther. 2021. PMID: 32721227
51 results